Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03340506

Title field or adapter rule

{'original_value': 'Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:36.629146+00:00

Published At

2026-10-22T00:00:00+00:00

Record Updated At

2026-10-22

Source Retrieved At

2026-10-31T22:19:02.163121+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Melanoma", "Non Small Cell Lung Cancer", "Solid Tumor", "Rare Cancers", "High Grade Glioma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-22", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT03340506"

protocolSection.identificationModule.officialTitle

"Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE4"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Melanoma (protocolSection.conditionsModule.conditions)
• Non Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Solid Tumor (protocolSection.conditionsModule.conditions)
• Rare Cancers (protocolSection.conditionsModule.conditions)
• High Grade Glioma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Combination therapy (dabrafenib & trametinib)', 'dabrafenib monotherapy'], 'description': 'dabrafenib is available in capsules (50mg and 75mg) taken twice a day', 'name': 'dabrafenib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Combination therapy (dabrafenib & trametinib)', 'trametinib monotherapy'], 'description': 'trametinib is available in tablets (0.5mg, 2mg dose)', 'name': 'trametinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• dabrafenib (protocolSection.armsInterventionsModule.interventions[].name)
• trametinib (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.